Article info

Download PDFPDF

Haematology patients infected with SARS-CoV-2, pretreated with eculizumab or siltuximab, develop oligosymptomatic disease
Free

Authors

  1. Correspondence to Dr Ciprian Tomuleasa, Iuliu Hagieganu University of Medicine and Pharmacy Faculty of Medicine, Cluj Napoca 400124, Romania; ciprian.tomuleasa{at}umfcluj.ro
View Full Text

Citation

Iluta S, Pasca S, Dima D, et al
Haematology patients infected with SARS-CoV-2, pretreated with eculizumab or siltuximab, develop oligosymptomatic disease

Publication history

  • First published February 4, 2021.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.